Your shopping cart is currently empty

DS-437 is a dual PRMT5/7 inhibitor with IC50 values of 6 μM and also inhibits DNMT3A and DNMT3B with IC50 values of 52 μM and 62 μM, respectively. Additionally, DS-437 inhibits the methylation of FOXP3.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $43 | 5 days | 5 days |
| Description | DS-437 is a dual PRMT5/7 inhibitor with IC50 values of 6 μM and also inhibits DNMT3A and DNMT3B with IC50 values of 52 μM and 62 μM, respectively. Additionally, DS-437 inhibits the methylation of FOXP3. |
| In vitro | DS-437 increased total CD8+?and CD8+ PD-1+ T cells [2]. DS-437 was able to inhibit the methylation of an H4[1–24] peptide by the PRMT5–MEP50 complex under balanced conditions (cofactor and substrate concentrations set at their respective?Km?values) in a dose-dependent manner (IC50: 5.9 μM) [1]. |
| In vivo | The combination of DS-437 and the anti-p185erbB2/neu?antibody 4D5 had even more dramatic effects. DS-437 (10 mg/kg; i.p.; 5 times a week) has some beneficial effects on inhibiting tumor growth [1]. |
| Molecular Weight | 397.45 |
| Formula | C15H23N7O4S |
| Cas No. | 1674364-87-4 |
| Smiles | CCNC(=O)NCCSC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12 |
| Relative Density. | 1.71 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.